NCT04086966

PSMA-PET/MRI for Radiation Treatment Planning in Patients With Locally Metastatic Prostate Cancer: A Pilot Study

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University of Alabama at Birmingham · Academic / Other
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This pilot study will investigate the use of PSMA-PET/MRI (Positron Emission Tomography/ Magnetic Resonance Imaging)to guide radiation treatment planning in patients with known or suspected locally metastatic prostate cancer at the time of diagnosis. Patients will undergo a single PSMA-PET/MRI (or PET/CT (Computed Tomography) in some circumstances) prior to initiation of treatment. Following development of a PSMA-PET guided radiation treatment plan, therapeutic radiation will be delivered per standard-of-care parameters and assessments of feasibility and tolerability will be performed.

Conditions

• Metastatic Prostate Cancer

Interventions

Type	Name	Description
DRUG	[68Ga]PSMA-PET/MRI or PET/CT	\[68Ga\]PSMA-PET/MRI or PET/CT

Timeline

• Start date: 2020-08-20
• Primary completion: 2022-02-23
• Completion: 2022-02-23
• First posted: 2019-09-12
• Last updated: 2024-04-26
• Results posted: 2024-04-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study